Go Pro
→ A Dark Day Is Coming to America (From TradeSmith) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
$4.46
-4.7%		$4.13
$1.21
▼
$3.81
$110.15M0.68261,100 shs274,478 shs
Briacell Therap stock logo
BCTX
Briacell Therap
$3.44
$3.35
$2.60
▼
$14.68
$29.93M1.1488,988 shs40,491 shs
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
$2.02
$1.83
$1.60
▼
$4.94
$116.06M3.28629,517 shs330,300 shs
Genelux Corporation stock logo
GNLX
Genelux
$2.74
+4.2%		$2.89
$2.29
▼
$8.53
$122.86M0.6288,622 shs462,787 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
-4.70%-6.30%+15.84%-5.11%+160.82%
Briacell Therap stock logo
BCTX
Briacell Therap
0.00%-5.49%-10.65%+13.91%-52.54%
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
0.00%+3.59%+11.60%-26.55%-27.08%
Genelux Corporation stock logo
GNLX
Genelux
0.00%+3.01%-2.84%-6.16%-14.38%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
$4.46
-4.7%		$4.13
$1.21
▼
$3.81
$110.15M0.68261,100 shs274,478 shs
Briacell Therap stock logo
BCTX
Briacell Therap
$3.44
$3.35
$2.60
▼
$14.68
$29.93M1.1488,988 shs40,491 shs
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
$2.02
$1.83
$1.60
▼
$4.94
$116.06M3.28629,517 shs330,300 shs
Genelux Corporation stock logo
GNLX
Genelux
$2.74
+4.2%		$2.89
$2.29
▼
$8.53
$122.86M0.6288,622 shs462,787 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
-4.70%-6.30%+15.84%-5.11%+160.82%
Briacell Therap stock logo
BCTX
Briacell Therap
0.00%-5.49%-10.65%+13.91%-52.54%
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
0.00%+3.59%+11.60%-26.55%-27.08%
Genelux Corporation stock logo
GNLX
Genelux
0.00%+3.01%-2.84%-6.16%-14.38%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
0.00
N/AN/AN/A
Briacell Therap stock logo
BCTX
Briacell Therap
1.00
SellN/AN/A
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
2.64
Moderate Buy$9.80385.15% Upside
Genelux Corporation stock logo
GNLX
Genelux
2.50
Moderate Buy$18.00556.93% Upside

Current Analyst Ratings Breakdown

Latest BCTX, BDTX, GNLX, and AADI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/6/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
8/6/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/6/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/17/2026
Briacell Therap stock logo
BCTX
Briacell Therap
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Genelux Corporation stock logo
GNLX
Genelux
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/13/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D) ➝ Sell (D-)
5/22/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
5/22/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
5/22/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
5/18/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D+) ➝ Sell (D)
(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
$25.07M4.39N/AN/A$4.29 per share1.04
Briacell Therap stock logo
BCTX
Briacell Therap
N/AN/AN/AN/A$9.20 per shareN/A
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
$70M1.66$0.53 per share3.83$1.97 per share1.03
Genelux Corporation stock logo
GNLX
Genelux
$10K12,286.16N/AN/A$0.30 per share9.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%N/A
Briacell Therap stock logo
BCTX
Briacell Therap
-$26.31M-$7.92N/AN/AN/AN/A-153.53%-129.26%N/A
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
$22.37M-$0.75N/AN/AN/AN/A-32.10%-25.21%N/A
Genelux Corporation stock logo
GNLX
Genelux
-$32.15M-$0.86N/AN/AN/AN/A-205.85%-138.79%11/4/2026 (Estimated)

Latest BCTX, BDTX, GNLX, and AADI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Genelux Corporation stock logo
GNLX
Genelux
-$0.1967-$0.21-$0.0133-$0.21N/AN/A
8/5/2026Q2 2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
-$0.1954-$0.17+$0.0254-$0.17$5.56 millionN/A
6/9/2026Q3 2026
Briacell Therap stock logo
BCTX
Briacell Therap
N/A-$0.99N/A-$0.99N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
N/AN/AN/AN/AN/A
Briacell Therap stock logo
BCTX
Briacell Therap
N/AN/AN/AN/AN/A
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
N/AN/AN/AN/AN/A
Genelux Corporation stock logo
GNLX
Genelux
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
N/A
4.89
4.54
Briacell Therap stock logo
BCTX
Briacell Therap
N/A
7.07
7.07
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
N/A
7.28
7.28
Genelux Corporation stock logo
GNLX
Genelux
N/A
2.39
2.39

Institutional Ownership

CompanyInstitutional Ownership
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
52.08%
Briacell Therap stock logo
BCTX
Briacell Therap
15.42%
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
95.47%
Genelux Corporation stock logo
GNLX
Genelux
37.33%

Insider Ownership

CompanyInsider Ownership
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
37.30%
Briacell Therap stock logo
BCTX
Briacell Therap
0.74%
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
9.29%
Genelux Corporation stock logo
GNLX
Genelux
7.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
4024.70 million15.49 millionNo Data
Briacell Therap stock logo
BCTX
Briacell Therap
88.70 million8.64 millionNo Data
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
9057.45 million52.12 millionOptionable
Genelux Corporation stock logo
GNLX
Genelux
1044.84 million41.48 millionNot Optionable

Recent News About These Companies

Genelux (NASDAQ:GNLX) Cut to "Strong Sell" at Wall Street Zen
August 15 at 2:06 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30961626
Genelux (NASDAQ:GNLX) Downgraded to "Strong Sell" Rating by Wall Street Zen
August 15 at 2:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/genelux-nasdaqgnlx-downgraded-to-strong-sell-rating-by-wall-street-zen-2026-08-15/
Genelux Reports Second Quarter 2026 Results and Advances Olvi-Vec Clinical Programs in Ovarian and Lung Cancer
August 13 at 4:51 PM  |  quiverquant.comQ
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
August 13 at 4:20 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344971/0/en/genelux-corporation-reports-second-quarter-financial-results-and-provides-business-updates.html
Genelux (NASDAQ:GNLX) Issues Earnings Results
August 13 at 1:40 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/genelux-nasdaqgnlx-issues-earnings-results-2026-08-13/
Genelux (GNLX) Expected to Announce Quarterly Earnings on Thursday
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/genelux-gnlx-expected-to-announce-quarterly-earnings-on-thursday-2026-07-30/
Genelux (NASDAQ:GNLX) Shares Down 2.4% - Should You Sell?
July 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/genelux-nasdaqgnlx-shares-down-24-should-you-sell-2026-07-24/
Genelux (GNLX) Stock Forecast & Price Target
July 11, 2026  |  investing.comhttps://www.investing.com/equities/genelux-consensus-estimates
Genelux (NASDAQ:GNLX) Director John Smither Sells 12,000 Shares of Stock
July 3, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-gnlx-insider-buying-and-selling-2026-07-03/
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
June 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/30/3319590/0/en/genelux-announces-publication-of-translational-analysis-supporting-immune-activation-and-chemotherapy-sensitization-with-olvi-vec-in-ovarian-cancer.html
Genelux Earnings Estimates, EPS & Revenue | NASDAQ:GNLX
June 29, 2026  |  benzinga.comhttps://www.benzinga.com/quote/GNLX/earnings
Insider Selling: Genelux (NASDAQ:GNLX) Director Sells 10,000 Shares of Stock
June 3, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-gnlx-insider-buying-and-selling-2026-06-03/
Genelux Corporation Common Stock (GNLX)
May 25, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/gnlx/institutional-holdings
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
May 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/07/3290643/0/en/genelux-corporation-reports-first-quarter-financial-results-and-provides-business-updates.html
Genelux Corporation Common Stock (GNLX) Real-Time
April 7, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/gnlx/real-time
Genelux Establishes $100 Million At-The-Market Equity Program
March 19, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/genelux-establishes-100-million-at-the-market-equity-program?utm_source=marketbeat.com&utm_medium=referral
Genelux Corporation Announces Phase 3 Trial Data Timeline and Interim Results for Olvi-Vec in Ovarian and Lung Cancer, Alongside Leadership Appointment
March 19, 2026  |  quiverquant.comQ
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/19/3259445/0/en/genelux-corporation-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-updates.html
Genelux (NASDAQ:GNLX) Director Sells $29,000.00 in Stock
March 4, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-gnlx-insider-buying-and-selling-2026-03-04/
Genelux Corporation to Participate in Upcoming Conferences
February 18, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/genelux-corporation-to-participate-in-upcoming-conferences-1035840032
Why Genelux Corporation’s (GNLX) Stock Is Up 9.50%
February 12, 2026  |  aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aadi Bioscience stock logo

Aadi Bioscience NASDAQ:AADI

$4.46 -0.22 (-4.70%)
As of 08/14/2026

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Briacell Therap stock logo

Briacell Therap NASDAQ:BCTX

$3.44 0.00 (0.00%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$3.42 -0.02 (-0.67%)
As of 08/14/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Black Diamond Therapeutics stock logo

Black Diamond Therapeutics NASDAQ:BDTX

$2.02 0.00 (0.00%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$2.04 +0.02 (+0.99%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Genelux stock logo

Genelux NASDAQ:GNLX

$2.74 +0.11 (+4.18%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$2.75 +0.01 (+0.36%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas